SINGAPORE / TORONTO / MIAMI — ALR Technologies SG Ltd. (ALRT) has officially scaled up the global commercial architecture for its GluCurve® Pet CGM, completing its major Canadian market entry (May 19–20, 2026). This follows a comprehensive corporate and manufacturing overhaul.
Developed in direct partnership with CGM Medical Technology Shenzhen Ltd. and manufactured at the high-spec Foxconn infrastructure facility in Shenzhen, the newly redesigned GluCurve hardware represents a major milestone: the world’s first and only continuous glucose monitoring system engineered from the ground up exclusively for veterinary use on domestic cats and dogs.
Clinical Imperative: Overcoming the Human CGM Adaptation Gap
For years, veterinary endocrinology relied on adapting human CGMs—primarily the Abbott FreeStyle Libre series—off-label for companion animals. However, human skin morphology, body temperature, interstitial fluid dynamics, and behavioral profiles differ fundamentally from those of canines and felines, causing frequent sensor errors, premature detachment, and data gaps.
Hardware & Architectural Specifications
The GluCurve system resolves these data collection challenges through tailored physical and electronic engineering:
-
Sampling Frequency: The wearable sensor automatically measures and logs interstitial glucose metrics every 3 minutes. This generates 480 discrete data points every 24 hours, compared to the 5-to-15-minute intervals typical of human monitors
-
Operational Lifespan: A single, painless veterinary application provides continuous, unbroken tracking for up to 14 days
-
Connectivity Module: Integrates an updated Bluetooth Low Energy (BLE) chipset configured with automated CGM fault detection and sensor-warmup tracking. This setup securely pushes real-time telemetry profiles directly to the companion iOS or Android consumer application
Software Ecosystem: AI Logistics and Cloud Portal Data Routing
The true competitive differentiator of the GluCurve system lies in its automated data routing and built-in clinical decision support tool:
1. Pet Owner Interface (App)
The localized mobile application serves strictly as a passive data collection point and an event logger. Pet owners use a streamlined user interface to record daily events, including exact insulin injection timestamps, meal volumes, and physical exercise blocks, matching these real-world events directly against the real-time glucose curve.
2. The ALRT Veterinary Web Portal
Raw data from the consumer app is instantly uploaded to a secure, cloud-hosted portal. The platform automatically organizes the 480 daily data points into clean, 24-hour trend lines. The portal features a multi-curve overlay function, allowing veterinarians to stack historical curves directly on top of current data to visually isolate immediate metabolic trends.
3. AI-Driven Automated Insulin Dosing Assistance
To streamline complex case management, the web portal runs incoming data lines through an algorithmic assessment engine. Based on peer-reviewed veterinary diabetes care guidelines, the software automatically calculates and outputs insulin dose and frequency suggestions. This allows practitioners to safely optimize treatment plans either during in-person checkups or via remote telemedicine workflows.
Market Dynamics, Projections, and Commercial Architecture
ALRT’s Animal Health division, led by Head of Animal Health Joe Stern, has structured a highly strategic commercial rollout designed to win the favor of independent clinics and corporate veterinary groups alike. Internal data metrics and companion animal population surveys indicate a massive global market opportunity:
-
Canada Market Potential: 150,000 to 300,000 units annually
-
United States Market Potential: 2.0 million to 3.0 million units annually
-
European & Global Potential: Up to 3.0 million units annually across Europe, Australia, and Asia-Pacific corridors
B2B Veterinary Commercial Protection Model
Unlike human CGMs, which are frequently purchased by consumers directly from human pharmacies (cutting veterinarians out of the revenue loop), GluCurve is sold directly to veterinary professionals.
The pricing structure is intentionally designed to allow veterinary clinics to earn healthy margins on both the hardware unit itself and the subsequent digital interpretation of the automated glucose curves. This lets clinics offer comprehensive 14-day monitoring to pet owners at a total cost that is highly competitive with traditional in-clinic curves, while securing superior clinical outcomes and better compliance.
Global Launch Timeline (Mid-2026 Expansion)
Following the formal Canadian market completion this week, ALRT’s commercial pipeline is moving through a structured, multi-phase global rollout:
-
United States Launch (Early Q2 2026): Moving through an ongoing strategic relationship with a major, Tier-1 North American veterinary distributor to secure instant penetration into thousands of animal hospitals
-
Global Phased Rollout (Late 2026): Launching dedicated commercial platforms across Western Europe, Australia, South America, and select Asian health sectors
